Shire (SHPG) Debt-to-Equity : 0.41 (As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire Debt-to-Equity?

Shire's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was $4,249 Mil. Shire's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was $11,098 Mil. Shire's Total Stockholders Equity for the quarter that ended in Sep. 2018 was $37,290 Mil. Shire's debt to equity for the quarter that ended in Sep. 2018 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shire's Debt-to-Equity or its related term are showing as below:

SHPG's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Shire Debt-to-Equity Historical Data

The historical data trend for Shire's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Debt-to-Equity Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.16

0.79

0.54

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Debt-to-Equity	Get a 7-Day Free Trial															0.63	0.54	0.50	0.49	0.41

Competitive Comparison of Shire's Debt-to-Equity

For the Biotechnology subindustry, Shire's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shire's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shire's Debt-to-Equity falls into.

Shire Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shire's Debt to Equity Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2788.7	+	16752.4)	/	36176.4
	=	0.54

Shire's Debt to Equity Ratio for the quarter that ended in Sep. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4248.7	+	11098)	/	37290.2
	=	0.41

Shire (NAS:SHPG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Shire Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shire's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085